PI: Dr. Esther Hulleman
(Combinational) Drug screens:
For the identification of compounds that effectively eradicate pediatric brain tumor cells, we perform (semi) high-throughput drug screens on primary cell cultures, either as monotherapy or in combination with other (epigenetic) drugs or gamma-irradiation. Radiotherapy is an important component of the current treatment schedules for most types of high-grade brain tumor in children, and – as such – should be considered when screening for novel agents. Drug screen libraries consist of both ‘classical chemotherapeutics’, and targeted agents: epigenetic-, kinase- or pathway inhibitors, depending on the methylation- and gene expression data of the primary tumor. In addition, the we use protein phosphorylation arrays that enable us to identify signal transduction routes that are essential for the growth of tumor cells, as well as pathways that are involved in escape mechanisms leading to drug resistance. This allows the logic design of combinational therapies, in which the drugs act with an additive or synergistic effect. Preferably, we test compounds that have been proven safe in children and approved for the European market, to enable a quick translation to the clinic.
Part of the drug discovery program involves tumor characterization for the design of targeted treatment. Besides target identification, such profiling is also important to study tumor biology, and to identify molecular subgroups with putative diagnostic- or prognostic- significance. In addition, we can use tumor profiling to monitor disease progression in time, and to identify resistance mechanisms that may result in therapy failure. As many brain tumor patients relapse, understanding such resistance mechanisms will be essential to ultimately improve survival. Phospho-proteomics can be used to identify signal transduction routes that are involved in drug resistance when measured before-, and after drug treatment. However, such drug resistance mechanisms should be studied both in vitro and in vivo, since most brain tumors are characterized by extensive heterogeneity, which is not reflected in cell cultures. Furthermore, in vivo experiments should focus not only on drug resistance, but also on radio-resistance (investigating both signal transduction- and DNA repair mechanisms), as the tumor microenvironment is thought to play an important role in the resistance of brain tumors to irradiation.
The minimal progress in the treatment of pediatric brain tumors in the past decades may be attributed to a limited drug distribution in the brain. Most chemotherapeutics – and small molecules in particular – are good substrates of drug efflux transporters, as they have historically been selected for their inability to pass the blood-brain-barrier (BBB) to minimalize neurological damage and treatment related side effects. However, good brain penetration and subsequent drug accumulation will be essential for the treatment of (pediatric) brain tumors. Thus, novel treatment strategies (both invasive- and non-invasive) need to be developed, such as convection enhanced-, intra-arterial-, or intranasal delivery, sonoporation, implanted therapies, the use of nanocarriers, chemical modification of parent drugs with vectors that help crossing the BBB, or co-administration of chemotherapeutic agents with compounds that open up the BBB.
Novel research models:Since the focus or our laboratory experiments is on translational projects, we need robust in vitro and in vivo models that mimic the molecular and histological phenotype of the tumors, to evaluate novel treatment modalities. Currently, such models are scarce, and most exhibit relatively slow tumor growth, making them unsuitable to test new therapies. Therefore, we routinely establish novel patient-derived xenograft (PDX) models for various forms of high-grade pediatric brain tumors from primary patient material. These models are extensively characterized on different levels (gene-expression profiles, genomic characteristics, and histology) and compared to the original tumor, to ensure their reliability. Besides drug testing, the PDX models can be used to study the blood-brain barrier, tumor biology, tumor-stroma interactions, or novel neurosurgical- and diagnostic techniques.
Overview of current drug delivery methods across the blood-brain barrier for the treatment of primary brain tumors. Haumann R, Carvalho Videira J, Kaspers GJL, van Vuurden DG, Hulleman E. (2020).. CNS Drugs, in press.
A high-throughput image-guided stereotactic neuronavigation and focused ultrasound system for blood-brain barrier opening in rodents. Haumann R, ‘t Hart E, Derieppe MPP, Besse HC, Kaspers GJL, Hoving E, van Vuurden DG, Hulleman E, Ries M. (2020). J Vis Exp (161).
Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Wiese M, Hamdan F, Kubiak K, Diederichs C, Gielen G, Nussbaumer G, Carcaboso A, Hulleman E, Johnsen S, Kramm C. (2020).. Cell Death Dis 11(8), 673.
Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso Á, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E. (2020). Clin Cancer Res, 26(13), 3319-3332.
Development of transient radioresistance during fractionated irradiation in vitro. Van den Berg J, Castricum KCM, Meel MH, Goedegebuure RSA, Lagerwaard FJ, Slotman BJ, Hulleman E*, Thijssen VLJL. (2020). Radiother Oncol 148, 107-114.
Immunotherapy in pediatric brain tumors: considerations, challenges and future directions. Kruithof ES, van der Lugt J, Hulleman E. (2019). J Mol Clin Med 2(3), 79-91.
Patient-derived orthotopic xenograft models of pediatric brain tumors: in a mature phase or still in its infancy? Hermans E, Hulleman E. (2019). Front Oncol 9, 14-18.
Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. Metselaar DS, Meel MH, Benedict B, Waranecki P, Koster J, Kaspers GJL, Hulleman E. (2019). Ebiomedicine 50, 81-92.
Signaling pathways and mesenchymal transition in pediatric high-grade glioma. Meel MH, Schaper SA, Kaspers GJL, Hulleman E. (2018). Cell Mol Life Sci, 75, 871-887. PubMed PMID: 29164272
Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Bugiani M, Veldhuijzen van Zanten SEM, Caretti V, Schellen P, Aronica E, Noske DP, Vandertop WP, Kaspers GJL, van Vuurden DG, Wesseling P, Hulleman E. (2017). Oncotarget 8, 60447-60452. PubMed PMID: 28947983
Preclinical evaluation of convection-enhanced delivery with liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Montero-Carcaboso A, Gaillard PJ, Vandertop WP, Wesseling P, Noske DP, Kaspers GJL, Hulleman E. (2017). J Neurosurg Pediatr 17, 1-13. PubMed PMID: 28291423
Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-Bevacizumab PET imaging in brain tumor models. Jansen MHA, Lagerweij T, Sewing ACP, Vugts DJ, van Vuurden DG, Molthoff CFM, Caretti V, Veringa SJE, Petersen N, Montero-Carcaboso A, Noske DP, Vandertop WP, Wesseling P, van Dongen GAMS, Kaspers GJL, Hulleman E. (2016). Mol Cancer Ther 15, 2166-2174. PubMed PMID: 27325687
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen s, Johung TB, Sun w, Kogiso M, Du Y, Qi L, Huang Y, Hutt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe E, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. (2015) Nat Med 21, 555-559. PubMed PMID: 25939062